On April 26th a working session took place within the scope of St.
Petersburg International Forum on pharmaceutics and biotechnologies; the
session was headed by the Minister of Industry and Trade of Russian
Federation V. Khristenko. The representatives of public authorities and
businesses met to discuss the current issues of pharmaceutical cluster
development: vice-governor of St. Petersburg - M. Oseevskiy, chairman of
the Committee for Economic Development, Industrial Policy and Trade -
E. Yelin, deputy chairman of the Committee for Economic Development,
Industrial Policy and Trade - Z. Golant, as well as the heads of the
leading pharmaceutical companies – among them the participants of St.
Petersburg pharmaceutical cluster.
SEZ "Neudorf" was specially chosen as the session site: in July 2010
in SEZ “Neudorf” hosted a gala-opening of the business center, the
Minister of Economic Development of the Russian Federation, E.
Nabiullina, among the participants. On the whole, 2010 was a year full
of important strategic decisions determining the development of the
pharmaceutical cluster of St. Petersburg in many ways: the concept of a
cluster was approved, a special industrial zone Pushkinskaya and a
special economic zone “Neudorf” were formed as a platform for scientific
research. At the opening ceremony of the center the SEZ residents
presented some R&D plans, and almost a year later the participants
of the session summarized the first intermediate results of their work,
and also discussed the prospects of the innovative development of the
One of the first R&D projects to be implemented in the SEZ
"Neudorf" was a project by GEROPHARM to create a research center of the
international level. Peter Rodionov, the CEO of GEROPHARM, emphasized
that the project, focused on the development of new drugs, will
contribute to the realization of the Federal Strategy PHARMA-2020. The
company plans to work on generic drugs which are a priority in terms of
import substitution and on some innovative drugs which will be used for
treating the socially significant diseases. The research will be mainly
focused on the synthesis of original substances, the development of the
innovative peptide and genetically engineered drugs, as well as the
diagnostic systems having no equivalents in the world, and will help to
diagnose the diseases at an early stage and monitor the effectiveness of
The long-term strategy of GEROPHARM provides the complex development: apart from the R&D center, the company is implementing a project of building a modern industrial complex that will be located in the pharmaceutical cluster in the Puskinskaya industrial zone. The pharmaceutical development, that is a complex of events focused on the development, analysis and the introduction of new drugs to be implemented in the research center of the company in SEZ “Neudorf”, will help to speed up the process of the adoption of laboratory products in the industrial production, and also to minimize the technical difficulties of this transitional stage.